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                                         ABSTRACT 
             A STUDY ON ECHOCARDIOGRAPHIC 
FINDINGS IN HIV-INFECTED PATIENTS AND THEIR 
CORRELATION WITH     CD4 COUNT 
Background and Purpose With advances in the management 
of patients with HIV and AIDS, not only survival has 
increased but manifestations of late stage HIV infection are 
encountered more often including cardiovascular complica-
tions. Cardiovascular disease has been reported as one of the 
leading causes of death in HIV-infected patients. In the 
present study our purpose was to study echocardiographic 
findings in HIV-infected patients and to correlate with CD4 
count. 
Methods We included 100 patients with HIV infection 
irrespective of the ART status.CD4 count was estimated for 
all the patients and all of them were subjected to 
Echocardiographic examination. 
Results When CD4 count was compared within the age group 
it was not statistically significant(p=0.098) and so was the 
comparison between the two sexes(p=0.529).The comparison 
of the CD4 count and ART status was statistically 
significant(p<0.001) and so was the comparison of LVDD 
among the study group(p<0.001). The comparison of CD4 
count with presence of Pericardial effusion was statistically 
significant (p=0.013) and so was the comparison of EF and 
PAH among the study group (p<0.001 for both).The 
comparison of CD4 with DCM was statistically 
insignificant(p=0.314). 
Conclusions Cardiovascular manifestations are common in 
HIV infected patients and often subclinical. Echocardiography 
is used for their early recognition and CD4 count correlates 
well with Echocardiographic findings. 
Key Words HIV -infection, AIDS, Antiretroviral 
Therapy,CD4 cell count ,Echocardiography. 
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INTRODUCTION 
Cardiovascular disease has been reported as one of the leading causes 
of death in HIV-infected patients. As the clinical presentation of HIV 
infection is still dominated by opportunistic infections, heart disease can be 
easily overlooked in these individuals. Moreover symptoms of 
breathlessness, fatigue and poor exercise tolerance are frequently ascribed to 
other conditions associated with HIV infection.  
Echocardiographic abnormalities are frequent in HIV-infected patients 
who do not have detectable clinical manifestations. Echocardiography is 
very helpful in detecting cardiac dysfunction at an early stage much before 
overt clinical manifestations and treatment of cardiac dysfunction in such 
patients.  
Most frequent echocardiographic abnormalities are reduced ejection 
fraction, pericardial effusion, dilated cardiomyopathy, diastolic dysfunction, 
regional wall motion abnormalities, pulmonary artery hypertension and 
others. 
In this present study I aim to analyze whether the echocardiographic 
abnormalities have any correlation with CD4 count.  
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AIMS AND OBJECTIVES 
 To study echocardiographic findings in HIV-infected patients. 
 To evaluate their correlation with CD4 count. 
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REVIEW OF LITERATURE 
HIV INFECTION AND AIDS: 
Human immunodeficiency virus (HIV) was unknown till the early 
1980's but since has infected millions of people in a worldwide 
pandemic.AIDS was first recognized in the United States in 1981, when the 
U.S. Centers for Disease Control and Prevention (CDC) reported the 
unexplained occurrence of Pneumocystis jiroveci pneumonia in five hitherto 
healthy homosexual men in Los Angeles and of Kaposi’s sarcoma (KS) in 
26 hitherto healthy homosexual men in New York and Los Angeles. 
In 1983, human immunodeficiency virus (HIV) was isolated from a 
patient with lymphadenopathy, and by 1984 it was demonstrated clearly to 
be the causative agent of AIDS. In 1985, a sensitive enzyme-linked 
immunosorbent assay (ELISA) was developed. Since then it has served as 
the basis for developing improvements in diagnosis. 
In India the first cases of HIV infection were documented among 
female sex workers in Chennai, Tamil Nadu in the year 1986. 
The result of HIV infection is devastation of the immune system 
leading to onset of the acquired immunodeficiency syndrome (AIDS). All 
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HIV-infected persons are at risk for illness and death from opportunistic 
infections and neoplastic complications because of the unavoidable 
manifestations of AIDS. 
In addition, therapy was dramatically changed with the introduction of 
antiretroviral drugs in 1987 and revolutionized by combination treatment, 
known as highly active antiretroviral therapy (HAART), in 1996. Three 
years after introducing HAART, mortality, AIDS, AIDS-defining diagnoses, 
and hospitalizations all decreased 60 to 80 percent. The EuroSIDA study, 
comparing this early HAART period to pre-HAART and later HAART 
(1998 to 2002) treatment periods, found a sustained decrease in mortality 
and progression to AIDS with ongoing HAART. Despite the absence of a 
cure, the natural history of the disease was radically changed. 
 
EPIDEMIOLOGY 
Global summary of the AIDS epidemics as on December 2009 1 
Number of people living with HIV in December 2009 
 Total  33.3 million (31.4 – 35.3 million) 
 Adults 32.8 million (30.9 – 34.7 million) 
 Women 22.5 million (20.9 – 24.2.million) 
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People newly infected with HIV in 2009 
 Total  2.6 million (2.3. – 2.8 million) 
 Adults 2.2 million (2.1 – 2.3 million) 
AIDS deaths in 2009 
 Total  1.8 million (1.6. – 2.1 million) 
 Adults 2.2 million (1.4 –  1.7 million) 
  
 Summary of AIDS Epidemic in India2 
Number of people living with HIV Infection                    
 Total 2.40 million (1.9-3.0 million) 
 Males 61%    
 Females 39% 
 Children 3.5% 
Prevalence among Adults        
 Overall 0.31% 
 Males 0.44% 
 Females 0.23% 
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ETIOLOGIC AGENT: 
HIV is the etiologic agent of AIDS; it belongs to the family of human 
retroviruses (Retroviridae) and the subfamily of lentiviruses. This subfamily 
has two types HIV-1 and HIV-2. The most common cause of HIV disease 
throughout the world is HIV-1, which includes several subtypes with 
different geographic distributions.HIV-2 was first identified in 1986 in West 
African patients and was originally confined to West Africa. 
The newly defined groups of HIV-1 (M, N, O, P) and the HIV-2 
groups A through G each are likely transferred to humans from a nonhuman 
primate reservoir. HIV-1 viruses likely came from chimpanzees and/or 
gorillas, and HIV-2 from sooty mangabeys. The AIDS pandemic is primarily 
caused by the HIV-1 M group viruses21.  
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HIV STRUCTURE: 
 
In electron microscopy the HIV virion shows an icosahedral 
.Structure. HIV is an enveloped positive stranded RNA virus that measures 
120 nm in diameter and has a lipid bilayer with uniformly arranged 72 
spikes  of glycoprotein – gp 120 and gp 41 (HIV-1)/gp 36 (HIV-2). The 
virion gp120 which is located on the virus surface contains the binding site 
for cellular receptor(s). The two plus stranded RNA molecules are enclosed 
in a protein capsid (p24) together with certain viral enzymes (viral RNA-
dependent DNA polymerase (Pol, also called the reverse transcriptase, RT 
(p66, p51) and nucleocapsid proteins (p9, p7). The capsid (p24) is 
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surrounded by a matrix layer (p17) that in turn is embedded in lipid bi-layer, 
the envelope. 
REPLICATION CYCLE OF HIV: 
HIV enters the body when a person comes in contact with infected 
blood, semen or vaginal secretions. The CD4 receptor is the principal target 
site for HIV, however specific chemokine receptors appear to be an 
important secondary cellular receptors for HIV. HIV-1 strains have been 
classified into 
T-tropic (preferring to replicate in T-lymphocytes) and M-tropic 
(macrophages) viruses. 
The chemokine receptor usage is distinct for each of these viruses, 
with T-tropic viruses making use of CD4 and CXCR4 (or fusin, the receptor 
for SDF-1), and M-tropic viruses making use of CD4 and CCR5 (receptor 
forRANTES). After attachment of CD4, gp120 is displaced leading to 
uncovering of domains on the envelope gp41 needed for virus cell fusion. 
Gp41 is involved in infectivity as well as syncytium formation. 
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After the viral capsid enters the cell, an enzyme called reverse 
transcriptase liberates the single-stranded RNA genome from the attached 
viral proteins and copies it into a complementary DNA (cDNA). The cDNA 
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and its complement form a double-stranded viral DNA which is then 
transported into the cell nucleus where it is integrated into the host cell’s 
genome by the enzyme called integrase. 
During viral replication, the integrated DNA provirus is transcribed 
into mRNA, which is then spliced into smaller pieces. These small pieces 
are exported from the nucleus into the cytoplasm, where they are translated 
into the proteins. The final step of the viral cycle, assembly of new HIV-1 
virion, begins at the plasma membrane of the host cell where the various 
structural components then assemble to produce a mature HIV virion. This 
cleavage step can be inhibited by protease inhibitors. The mature virus is 
then able to infect another cell. 
DEFINITION: 
THE CDC CLASSIFICATION: 
The current CDC classification system for HIV-infected adolescents 
and adults classify persons on the basis of clinical conditions associated with 
HIV infection and CD4+ T lymphocyte counts. 
 The system is based on three ranges of CD4+ T lymphocyte counts and 
three clinical categories and is depicted by a matrix of nine mutually 
exclusive categories. 
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 Using this system, any HIV-infected individual with a CD4+ T cell 
count of <200/µL has AIDS by definition, irrespective of the presence of 
symptoms or opportunistic diseases. Once individuals have had a clinical 
condition in category B, their disease classification cannot be reverted back 
to category A, even if the condition resolves; the same for category C in 
relation to category B. 
 
 
Category A: 
Conditions listed in categories B and C must not have occurred. 
 Asymptomatic HIV infection 
 Persistent generalized lymphadenopathy 
 Acute (Primary) HIV infection with accompanying illness or 
history of acute HIV infection. 
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Category B: 
Consists of symptomatic conditions in an HIV-infected adolescent or 
adult that are not included among conditions listed in clinical category C and 
meet at least one of the following criteria: 
1. The conditions are attributed to HIV infection or are of a 
defect in cell-mediated immunity; or 
2. The conditions are considered by physicians to have a 
clinical course or to require management and complicated 
by HIV infection.  Examples  
 Bacilliary angiomatosis 
 Candidiasis, oropharyngeal (thrush) 
 Candidiasis, vulvovaginal; persistent, frequent, or poorly 
response to therapy. 
 Cervical dysplasia (moderate or severe)/cervical 
carcinoma in situ. 
 Constitutional symptoms, such as diarrhea lasting 
>1month or fever (38.5°C). 
 Hairy leukoplakia, 
 Herpes zoster (shingles), involving at least two distinct 
episodes or more than one dermatome. 
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 Idiopathic thrombocytopenic purpura 
 Listeriosis 
 Pelvic inflammatory disease, if complicated by 
tuboovarian abscess. 
 Peripheral neuropathy 
Category C: 
 Candidiasis of bronchi, trachea, lungs or esophagus 
 Cervical cancer invasive 
 Coccidioidomycosis disseminated or extra pulmonary 
 Extra pulmonary Cryptococcosis , 
 Cryptosporidiosis- intestinal (>1 month) 
 Cytomegalovirus disease other than spleen, liver, or node 
 HIV encephalopathy 
 Herpes simplex, chronic (>1 month), or bronchitis, pneumonia, or 
esophagitis. 
 Histoplasmosis, disseminated or extra pulmonary 
 Isosporiasis - intestinal (>1 month) 
 Kaposi sarcoma 
 Lymphoma (Burkitt’s primary CNS) 
 MAC disseminated or extra pulmonary 
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 M. tuberculosis - any site 
 Pneumocystis carinii pneumonia 
 Pneumonia- recurrent 
 Progressive multifocal leukoencephalopathy 
 Salmonella septicaemia, recurrent 
 Toxoplasmosis- brain 
 Wasting syndrome - HIV 
 
Case Definition  - India ( above 12 years of Age) 
1. Two positive tests for HIV infection by ERS test 
(Elisa/Rapid/Simple) AND 
2. Any one -criteria: 
a. Significant weight loss (>10% of body weight) within last 1 
month/cachexia (rather than HIV infection).   AND Chronic 
diarrhea (intermittent or continuous) >one month duration or 
prolonged fever (intermittent or continuous) >one month 
duration.   
a. Tuberculosis: Extensive pulmonary, disseminated, 
milliary,extra-pulmonary tuberculosis.   
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b. Neurological impairment preventing independent daily 
activities, not known to be due to the conditions unrelated to 
HIV infection (e.g. trauma) 
c. Candidiasis of the oesophagus (diagnosable by oral 
candidiasis by odynophagia) 
d. Clinically diagnosed life threatening or multiple episodes of 
pneumonia, with or without etiological confirmation. 
e. Kaposi Sarcoma 
f. Other conditions: 
i. Cryptococcal meningitis 
ii. Neuro Toxoplasmosis 
iii. CMV retinitis 
iv. P.marneffei 
v. Recurrent Herpes Zoster or multi-dermatomal herpes 
infection 
vi. Disseminated molluscum 
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TRANSMISSION: 
The major routes for HIV transmission are: 
 Unprotected sexual intercourse with an HIV-infected partner. 
 Through transfusion of contaminated blood or blood products. 
 Among injection drug users via sharing of contaminated needles and 
syringes. 
 Intrapartum or perinatally from mother to infant; or via breast milk. 
There is no evidence that the virus can be transmitted through casual 
or family contact or by insects such as mosquitoes. 
There is a definite, though small, occupational risk of infection for 
laboratory personnel who work with HIV-infected specimens and for health 
care workers. The chances of transmission of HIV from an infected health 
care worker to his or her patients through invasive procedures is extremely 
low. 
RISKFACTORS: 
 Viral load11-The mean viral load was significantly higher in those 
who transmitted HIV to their partner.The importance of viral load is 
that a large proportion of HIV infections may be transmitted by 
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individuals with primary infection. This is due to the high levels of 
viremia that are seen in the setting of acute infection. 
 Sexually transmitted diseases14-The presence of sexually transmitted 
diseases also increases the risk of HIV transmission.The probability of 
transmission was nearly four times higher in patients with genital 
ulceration compared to those without. 
 Sexual risk -risk factors for HIV seroconversion included history of a 
multiple sexual partners, unprotected receptive anal sex with a partner 
with an unknown HIV serostatus, and use of nitrate inhalants. 
 Lack of circumcision10-Lack of circumcision is associated with risk 
of HIV transmission in groups of heterosexual couples and MSM. 
 Genetic background- Similarity of HLA-class-I alleles between HIV 
discordant couples may affect the risk of transmission, by selecting 
for viral strains that are more likely to escape the immune 
containment of the seronegative partner 
PATHOPHYSIOLOGY AND IMMUNOPATHOGENESIS: 
The distinctive characteristic of HIV disease is a profound 
immunodeficiency resulting from a progressive quantitative and also 
qualitative deficiency of the subset of T lymphocytes referred to as helper T 
cells. This subset of T cells is defined phenotypically by the expression on 
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the cell surface of the CD4 molecule, which serves as the primary cellular 
receptor for HIV. 
 A co-receptor must be present with CD4 for efficient entry of HIV -1 
into target cells. The two major co-receptors for HIV-1 are the chemokine 
receptors CCRS and CXCR4. The CD4+ T lymphocyte and CD4+ monocyte 
lineage are the principal cellular targets of HIV. 
Primary Infection : 
After initial transmission, the virus infects CD4+ cells, probably T 
lymphocytes, monocytes, or bone marrow-derived dendritic cells. Both 
during this initial stage and later in infection, the lymphoid system is a 
important site for the establishment and propagation of HIV infection. The 
gut-associated lymphoid tissue (GALT) plays a major role in the 
establishment of infection and in the early depletion of memory CD4+ T 
cells. 
Basically allpatients undergo a viremic stage during primary infection; 
in some patients this is associated with the "acute retroviral syndrome:' a 
mononucleosis-like illness. This phase is important in disseminating virus to 
lymphoid and other organs throughout the body, and it is ultimately 
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contained partially by the development of an HIV-specific immune 
response. 
Establishment of Chronic and Persistent Infection: 
Despite the powerful immune response that is mounted following 
primary infection, the virus is not cleared from the body. Instead, a chronic 
infection develops that persists for a median period of 10 years before the 
untreated patient becomes clinically ill. During this period of what appears 
to be clinical latency, the number of CD4+ T cells gradually declines, but 
few, if any, clinical signs and symptoms may be apparent. However, active 
viral replication can almost always be detected by measurable plasma 
viremia and the demonstration of virus replication in lymphoid tissue. 
The level of steady-state viremia at -6 months to 1 year postinfection 
has important prognostic implications for the progression of HIV disease; 
individuals with a low viral set point at 6 months to 1 year after infection 
progress to AIDS more slowly than do those whose set point is very high at 
this time. 
Advanced HIV Disease: 
In untreated patients  or in patients in whom therapy has not 
controlled viral replication, after some period of time CD4+ T cell counts 
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will fall below a critical level (~200/flL) and patients become highly 
susceptible to opportunistic disease. The presence of a CD4+ T cell count of 
<200/flL or an AIDS-defining opportunistic disease establishes a diagnosis 
of AIDS. 
Control of plasma viremia by successful antiretroviral therapy, 
particularly maintaining the plasma viral load consistently at <50 copies of 
RNA per mL, even in individuals with low CD4+ T cell counts, has  
increased survival in these patients dramatically, including those whose 
CD4+ T cell counts may not increase significantly as a result of therapy . 
IMMUNE ABNORMALITIES IN HIV DISEASE: 
A wide range of immune abnormalities has been documented in HIV 
infected patients, resulting in different degrees of immunodeficiency. These 
include both quantitative and qualitative defects in lymphocytes, and 
qualitative defects in monocyte/macrophage and natural killer (NK) cell 
function. Autoimmune phenomena also have been observed in HIV-infected 
individuals. 
IMMUNE RESPONSE TO HIV INFECTION: 
Both humoral and cellular immune responses to HIV develop soon 
after primary infection. 
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Humoral immunity includes: 
 Binding antibodies 
 Neutralizing antibodies 
 Type specific 
 Group specific 
 Antibodies participating in antibody-dependent cellular cytotoxicity 
(ADCC) 
 Protective 
 Pathogenic (bystander killing) 
 Enhancing antibodies 
 Complement. 
Cell-mediated immunityincludes: 
 Helper CD4+ T lymphocytes 
 Class I MHC–restricted cytotoxic CD8+ T lymphocytes 
 CD8+ T cell–mediated inhibition (noncytolytic) 
 ADCC 
 Natural killer cells. 
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CLINICAL MANIFESTATIONS:4 
The clinical outcome  of HIV infection include a spectrum ranging 
from an acute syndrome associated with primary infection to a prolonged 
asymptomatic state to advanced disease.  HIV disease begins at the time of 
primary infection and progresses through various stages. 
Active virus replication and progressive immunologic impairment 
occur throughout the course of HIV infection in most patients. With the 
exception of the rare, long-term nonprogressors HIV disease in untreated 
patients inevitably progresses even during the clinically latent stage. 
THE ACUTE HIV SYNDROME: 
It is estimated that 50–70% of individuals with HIV infection 
experience an acute clinical syndrome ~3–6 weeks after primary infection.It 
can have multiple clinical features, lasts 1-2 weeks, and resolves 
spontaneously as an immune response to HIV develops and the viral load 
declines from its peak levels. Most patient after that enter a phase of clinical 
latency. 
Approximately 10% of patients can manifest a fulminant course of 
immunologic and clinical deterioration after primary infection, which can 
occur even after the disappearance of initial symptoms. 
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 Clinical findings in the acute HIV syndrome are: 
General 
 Fever  
 Pharyngitis 
 Lymphadenopathy 
 Headache 
 Retroorbital pain 
 Arthralgia 
 Myalgia 
 Lethargy 
 Malaise 
 Anorexia 
 Weight loss 
 Nausea 
 Vomiting 
 Diarrhea 
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Neurologic: 
 Meningitis 
 Encephalitis 
 Peripheral neuropathy 
 Myelopathy 
Dermatologic: 
 Erythematous maculopapular rash 
 Mucocutaneous ulceration 
 
THE ASYMPTOMATIC STAGE—CLINICAL LATENCY: 
 
The length of time between the initial HIV infection and development 
of disease in untreated individuals varies greatly, but the median time is 
estimated to be 10 years. HIV disease with active viral replication usually 
progresses during this asymptomatic period, and CD4+ T cell counts fall.  
The rate of disease progression is directly correlated with plasma HIV 
RNA levels. Patients with high levels of HIV RNA progress to symptomatic 
disease faster than patient with low levels of HIV RNA. 
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 Some patients referred to as long-term nonprogressors show little if 
any decline in CD4+ T cell counts over extended periods of time. These 
patients generally have extremely low levels of HIV RNA; a subset, referred 
to as elite nonprogressors, exhibits HIV RNA levels <50 copies per 
milliliter. 
SYMPTOMATIC DISEASE: 
Symptoms of HIV disease can manifest at any time during the course 
of HIV infection. In general, the spectrum of illness changes as the CD4+ T 
cell count declines. The more severe and life-threatening complications of 
HIV infection occur in patient with CD4+ T cell counts <200/f.IL. Overall, 
the clinical spectrum of HIV disease is constantly changing as patient live 
longer and new and better treatment approaches and prophylaxis of 
opportunistic infections are developed. 
In addition, a variety of neurologic, cardiovascular, renal, metabolic, 
and hepatic problems are increasingly seen in patient with HIV infection and 
may be a direct consequence of HIV infection. The key element to treating 
symptomatic complications of HIV disease, whether primary or secondary, 
is achieving good control of HIV replication through the use of combination 
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antiretroviral therapy and starting primary and secondary prophylaxis as 
indicated. 
Major clinical syndromes are summarized below: 
CARDIOVASCULAR MANIFESTATIONS: 
 Coronary heart disease-myocardial infarction 
 HIV-associated cardiomyopathy 
 Myocarditis-Kaposi sarcoma, cryptococcosis, Chagas’ disease, 
and toxoplasmosis 
 Pericardial effusions, Cardiac tamponade 
 Malignant lymphoma 
 Diastolic dysfunction, systolic dysfunction 
 Right ventricular hypertrophy 
 Pulmonary arterial hypertension 
 Non-bacterial thrombotic endocarditis. 
PULMONARY MANIFESTATIONS: 
 Acute bronchitis and sinusitis 
 Bacterial pneumonia 
 Pneumocystis pneumonia (PCP) 
 Mycobacterium tuberculosis 
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 Atypical mycobacterial infections 
 Idiopathic interstitial pneumonia: lymphoid interstitial 
pneumonitis (LIP) and nonspecific interstitial pneumonitis 
(NIP). 
 
GASTROINTESTINAL MANIFESTATIONS: 
 Thrush 
 Hairy leukoplakia  
 Aphthous ulcers 
 Esophagitis 
 Diarrhea 
 HIV enteropathy 
 
HEPATOBILIARY MANIFESTATIONS:19. 
 Co-infection with hepatitis B, C 
 AIDS cholangiopathy 
 Granulomatous hepatitis 
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NEUROLOGICAL MANIFESTATIONS: 
 Neoplasms 
Primary CNS lymphoma 
Kaposi’s sarcoma 
 HIV encephalopathy 
 Myelopathy 
Vacuolar myelopathy 
  Pure sensory ataxia 
  Paresthesia/dysesthesia 
 Peripheral neuropathy 
Guillain-Barré syndrome 
Mononeuritis multiplex 
 
RENAL MANIFESTATIONS: 
 HIV-associated nephropathy 
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HAEMATOLOGICAL MANIFESTATIONS: 
 Anemia 
 Persistent generalised lymphadenopathy  
 Leukopenia,  
 Thrombocytopenia 
 
RHEUMATOLOGICAL MANIFESTATIONS:  
 Reiter’s syndrome, 
 Non-specific reactive arthritis 
 Septic arthritis. 
 Diffuse infiltrative lymphocytosis syndrome 
 Myopathy, 
 Vasculitis 
 AIDS-associated arthropathy 
ENDOCRINE AND METABOLIC DISORDERS: 
 Hypogonadism 
 Hypothyroidism 
 Hyperthyroidism 
 HIV-Associated Wasting 
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NEOPLASTIC DISEASES: 
 Kaposi's sarcoma (cutaneous and visceral, more fulminant course      
than in non-HIV-infected patients). 
 Lymphoma (primarily B cell, may be CNS or systemic). 
 
OPPORTUNISTIC INFECTION: 
 P. jiroveci (pneumonia) 
 CMV (chorioretinitis, colitis, pneumonitis, adrenalitis) 
 Candida albicans (oral thrush, esophagitis) 
 M. avium intracellulare (localized or disseminated infection) 
 M. disseminated disease) 
 Toxoplasma gondii (encephalitis, intracerebral mass lesion) 
 Herpes simplex virus (severe mucocutaneous lesions, 
esophagitis) 
 Diarrhea due to Cryptosporidium spp. or Isospora belli 
(diarrhea) 
 JC virus (progressive multifocal leukoencephalopathy) 
 Bacterial pathogens (pneumonia, sinusitis, skin). 
 Tuberculosis (pulmonary or disseminated), 
 Cryptococcus   neoformans  (meningitis,disseminated disease), 
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LABORATORY DIAGNOSIS OF HIV INFECTION:3 
Diagnosis of HIV infection can be achieved by the detection of: 
(a) antibodies in blood and body fluids 
(b) antigen in blood and body fluids 
(c) viral nucleic acid by polymerase chain reaction (PCR) 
(d) virus isolation from blood and tissues. 
According to NACO, a three-tiered strategy is adopted for diagnosis 
of HIV infection in clinical settings. Initially, a sample is tested by an 
ELISA/rapid test. If it is found reactive it is subjected to second and third 
ELISA/rapid assay using different antigen or principle of testing. 
 If all three tests are reactive, the samples are considered positive for 
antibodies against HIV. Samples that are negative in the first and second 
levels of testing are considered negative while samples that are positive in 
the two tests and negative in the third are considered equivocal and 
subjected to western blot for confirmation. 
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Detection of HIV Specific Antibodies5: 
Immunoassays for the detection of a serological response to HIV-1 
infection were developed in a series of stages, called generations. The first 
generation assays were very sensitive but not specific and the technology 
was later improved by using recombinant and synthetic peptides as antigens 
(2nd and 3rd generation kits). More recently, 4th generation ELISA tests 
have been developed that detect both antibodyand p24 antigen 
simultaneously. 
The different HIV-1 antibody detection tests currently available are 
ELISA, rapid immunoassays such as HIV spot tests, immuno Combs’ tests, 
dot blot immunoassays and agglutination assay (Capillus). Antibodies to 
HIV-2 in clinical samples were detected by ELISA with synthetic gp36 (TM 
portion of the HIV-2 envelope) antigens 
Detection of Viral Antigen in Blood and Body Fluids: 
The p24 antigen assay detects the viral capsid p24 protein in blood 
which is detected earlier than HIV antibody during acute infection. The most 
commonly used HIV p24 antigen test procedure is a basic antibody-
sandwich ELISA. This test is of limited diagnostic potential because 
antigenaemia is restricted to two stages of HIV infection: early in the illness 
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during the latter half of the window period and late in the illness (end-stages) 
when immune collapse has set in. 
Detection of Viral Nucleic Acid: 
Detection of HIV nucleic acid in plasma/serum is used for diagnosis 
of HIV infection in children aged less than 18 months (early infant diagnosis 
or EID) and estimation of viral loads. The detection of HIV nucleic acid can 
be achieved by either polymerase chain reaction (PCR), nucleic acid 
sequence based amplification (NASBA) or branched DNA (bDNA) 
technique. 
However, the most widely used test is the polymerase chain reaction 
(PCR). For EID, the NACO recommends the use of a HIV DNA PCR using 
dried blood spot specimens. 
TREATMENT 
Following a diagnosis of HIV infection, there are severalexaminations 
and laboratory studies that should be performed to help determine the extent 
of disease and provide baselinestandards for future reference. 
 History and physical examination 
 Routine chemistry and hematology 
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 AST, ALT, direct and indirect bilirubin 
 Lipid profile and fasting glucose 
 CD4+ count  
 Two plasma HIV RNA levels 
 HIV resistance testing 
 HLA-B5701 screening 
 RPR or VDRL test 
 Anti-Toxoplasma antibody titer 
 PPD skin test 
 Mini-Mental Status Examination 
 Serologies for hepatitis A, hepatitis B, and hepatitis C 
 Immunization with pneumococcal polysaccharide; influenza as 
indicated 
 Immunization with hepatitis A and hepatitis B if seronegative. 
ANTIRETROVIRAL THERAPY: 
          The cornerstone of medical management of HIV infection is 
combination antiretroviral therapy, (cART) or highly active antiretroviral 
therapy (HAART).20 
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 Suppression of HIV replication is an important component in 
prolonging life as well as in improving the quality of life of patients with 
HIV infection. 
 However, several important questions related to the treatment of HIV 
disease lack definitive answers. Among them are questions regarding when 
antiretroviral therapy should be started, what the best cART regimen is, 
when a given regimen should be changed, and which drugs in a regimen 
should be changed when a change is made. 
Antiretroviral therapy can also be used to reduce the risk of vertical 
transmission. 
The ARVs can be used after exposure  to HIV too, as in cases of 
accidental needle stick injury, and in cases of  sexual assault and rape. It is 
called post-exposure prophylaxis (PEP). 
HAART:  
These drugs fall into four main categories: 
1. Drugs that inhibit the viral reverse transcriptase enzyme, 
2. Drugs that inhibit the viral protease enzyme, 
3. Drugs that inhibit viral entry, and   
4. Drugs that inhibit the viral integrase 
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Mechanism of Drug Action: 
1. Nucleoside/Nucleotide Analogues These agents act by causing premature 
DNA-chain termination during the reverse transcription of viralRNA to 
proviral DNA and should be used in combination with otherantiretroviral 
drugs. The most common usage is combination with another 
nucleoside/nucleotide analogue and a nonnucleoside reverse transcriptase 
inhibitor or a protease inhibitor. 
2. Nonnucleoside Reverse Transcriptase Inhibitors These agents interfere 
with the function of HIV-1 reverse transcriptase by binding to 
regionsoutside the active site and causing conformational changes in 
theenzyme that render it inactive. These agents are very potent; 
however,when they are used as monotherapy, they result in the rapid 
emergenceof drug-resistant mutants. 
3. Protease Inhibitors These drugs are potent and selective inhibitors 
of the HIV-1 protease enzyme and are active in the nanomolar range. 
rapid emergence of resistant isolates when these drugs are used as 
monotherapy. Thus,the protease inhibitors should be used only in 
combination with other antiretroviral drugs.  
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4. HIV Entry Inhibitors These agents act by interfering with the binding of 
HIV to its receptor or co-receptor or by interfering with the process of 
fusion. A variety of small molecules that bind to HIV-1 co-receptors are 
currently in clinical trials. 
5. HIV lntegrase Inhibitors These drugs interfere with the integration of 
proviral DNA into the host cell genome. The first agent in this 
class,raltegravir, was approved in 2007 for use in treatment-experienced 
patients. 
CLASS SPECIFIC TOXICITIES 
1. NRTIs :  
 Hepatotoxicity   
 Lactic acidosis 
 Peripheral neuropathy 
 Pancreatitis 
2. NNRTIs: 
 Rash 
 Hepatitis 
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3. Protease Inhibitors 
 Hyperglycemia 
 Fat maldistribution (Lipodystrophy) 
 Hyperlipidemia 
 Increased bleeding episodes in patients with hemophilia   
 A vascular necrosis 
 G.I. intolerance and hepatitis 
 
INDICATIONS TO START ANTIRETROVIRAL THERAPY 
Table – Indications for the initiation of ART6,7,8. 
 
I. Acute infection syndrome 
 
II. Chronic infection 
 
a. Symptomatic state (including HIV-associated nephropathy) 
 
b. Asymptomatic state 
 
1. CD4+  count <500/L 
 
    2.  Pregnancy 
III. Postexposure prophylaxis 
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According to NACO Guidelines 
ClinicalCD4 count available 
Stage I or II ART if CD4 <350/mm3 
Stage III and IV ART regardless of CD4. 
At present, a reasonable course of action is to initiate HAARTin 
anyone with the acute HIV syndrome; all pregnant women;patients with an 
AIDS-defining illness; patients with HIVassociatednephropathy; patients 
with hepatitis B infectionwhen treatment for hepatitis B is indicated, and 
patients with asymptomatic disease with CD4+ T cell counts <500mm3. 
 The two options for initial therapy most commonly in use today are  
 (1) Two nucleoside/nucleotide analogues (one of which is usually 
tenofovir or abacavir, and the other of which is usually lamivudine or 
emtricitabine) combined with a protease inhibitor; or  
 (2) two nucleoside/nucleotide analogues and a nonnucleoside reverse 
transcriptase inhibitor. 
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INDICATIONS FOR CHANGING ANTIRETROVIRAL THERAPY 
IN PATIENTS WITH HIV INFECTION 
• Less than a 1-log drop in plasma HIV RNA by 4 weeks following 
the initiation of therapy 
• A reproducible significant increase (defined as 3-fold or greater) 
from the nadir of plasma HIV RNA level not attributable to 
intercurrent infection, vaccination, or test methodology 
• Persistently declining CD4+ T cell numbers 
• Clinical deterioration 
•
 Side effects 
ECHOCARDIOGRAPHY18 
EVALUATION OF SYSTOLIC FUNCTION: 
Several parameters are used for evaluation of systolic function of the 
heart. These parameters are LVEF, stroke volume and cardiac index, systolic 
tissue velocity of the mitral annulus and myocardium, strain, and regional 
wall motion analysis. 
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LEFT VENTRICULAR EJECTION FRACTION: 
 The most well accepted expression of global LV function is LVEF. In 
clinical practice, LVEF is usually determined by visual assessment of two-
dimensional echocardiographic images of the left ventricle. 
 LVEF should be measured more objectively whenever possible, using 
volumetric measurements as described by the following equation: 
                     LVEF = (LVEDV − LVESV) /LVEDV 
Where LVEDV and LVESV are LV end-diastolic volume and end-
systolic volume, respectively. 
          LVEF can also be calculated from LV dimensions measured with M-
mode or two-dimensional echocardiography. M-mode or two -dimensional 
echocardiographic measurement of LV dimensions from the mid-ventricular 
level is used to calculate LVEF as follows: 
                           LVEF = (LVEDD2 − LVESD2 )/ LVEDD2 
where LVEDD and LVESD are end-diastolic dimension and 
endsystolic dimension, respectively. 
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Grading of systolic dysfunction (American Society of 
Echocardiography): 
Ejection fractionsystolic dysfunction 
>55%                                      normal 
 45% - 54% mild systolic dysfunction 
30% - 44%                        moderate systolic dysfunction 
<30%                                  severe systolic dysfunction 
ASSESSMENT OF DIASTOLIC FUNCTION: 
              Assessment of diastolic function should be an integral part of an 
evaluation of cardiac evaluation because about 50% of patients with heart 
failure have preserved LVEF. 
              Assessment of diastolic function requires an understanding of 
diastology and various means to evaluate diastolic function. Currently, 
echocardiography is the best noninvasive way to evaluate diastolic function 
and to estimate filling pressures. 
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            LV diastolic filling consists of a series of events that are affected by 
numerous factors, including myocardial relaxation, compliance, cardiac 
rhythm, and pericardial compliance. 
Normal diastolic function ensures adequate filling of the ventricles 
during rest and exercise without an abnormal increase in diastolic pressure 
or pulmonary venous congestion. The initial diastolic event that happens is 
myocardial relaxation, an active energy-dependent process that causes LV 
pressure to decrease rapidly after the end of contraction. When LV pressure 
falls below LA pressure, the mitral valve opens, and rapid early diastolic 
filling begins. 
       The proportion of LV filling during the early and late diastolic phases 
depends on elastic recoil , rate of myocardial relaxation, chamber 
compliance, LA pressure, and heart rate. 
 Several parameters are used for grading of diastolic dysfunction. In 
most cardiac diseases, the initial diastolic abnormality is impaired relaxation. 
With further progression of disease and a mild to moderate increase in LA 
pressure, the mitral inflow velocity pattern appears similar to a normal 
filling pattern (pseudonormalized). With further decrease in LV compliance 
and increase in LA pressure, diastolic filling becomes restrictive. 
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       Most patients with restrictive filling are symptomatic and have a poor 
prognosis unless the restrictive filling can be reversed by treatment. 
However, restrictive filling may be irreversible and represent the end stage 
of diastolic heart failure. 
 Grading of diastolic dysfunction: 
GRADE diastolicdysfunction 
   0     normal 
   1     (mild dysfunction): impaired relaxation with    
          normal filling pressure .       
  2      (moderate dysfunction): pseudonormalized mitral  
          inflow pattern. 
  3     (severe reversible dysfunction): reversible             
 restrictive (high filling pressure)     
4         (severe irreversible dysfunction): irreversible       
 restrictive (high filling pressure) .      
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 DILATED CARDIOMYOPATHY: 
 This is basically characterised by enlarged LV cavity  and global 
systolic function is decreased. 
 End-diastolic and end-systolic dimensions and volumes are increased, 
and systolic function is decreased. With gradual dilation, the LV cavity 
which becomes more spherical, with a sphericity index (short-axis 
dimension/long-axis dimension) nearing the value of 1 (normally, ≥1.5). 
  LV mass is uniformly  increased (eccentric hypertrophy), and wall 
thickness is typically within normal limits. Ventricular contractility usually 
is globally reduced, but regional wall motion abnormalities can be present. 
 Secondary features may be identified by echocardiography in patients 
with dilated cardiomyopathy. These include dilated mitral annulus with 
incomplete mitral leaflet coaptation causing functional MR, evidence of low 
cardiac output (decreased excursion of mitral leaflets), enlarged atrial 
cavities, RV enlargement, and occasionally apical mural thrombus. 
 Echocardiography also plays a role in assessing the prognosis. Some 
of the determining prognostic factors are22. 
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 (a) degree of cardiomegaly; 
 (b) degree of LV dysfunction; 
 (c) extent of wall thickness of ventricles; 
 (d) pulmonary hypertension; 
 (e) restrictive filling pattern as assessed by mitral inflow Doppler; and 
 (f) some tissue Doppler imaging parameters. 
PERICARDIAL EFFUSION: 
 Echocardiography is the diagnostic modality of choice for detecting, 
quantifying, and assessing the hemodynamic impact of pericardial effusions 
and can often provide additional information about the pericardial contents. 
 A separation of pericardial fluid between the visceral and parietal 
layers of the pericardium  that persists through diastole as well as systole 
represents a small effusion. Small effusions tend to pool at the baseof the 
heart. 
 Moderate-sized effusions are visible circumferentially as echo-free 
regions anterior to the right ventricular (RV) free wall and posterior to the 
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left ventricle. As an effusion enlarges, it extends apically, laterally and then 
anteriorly becoming circumferential. 
PULMONARY ARTERY HYPERTENSION: 
 Echocardiography usually demonstrates enlargement of the right 
atrium and ventricle, normal or small left ventricular dimensions, and a 
thickened interventricular septum. 
 Right ventricular dysfunction is difficult to measure 
echocardiographically, but the position and curvature of the intraventricular 
septum provide an indication of right ventricular afterload. 
 Echocardiographic findings that indicate a poor prognosis include 
pericardial effusion and a markedly diminished left ventricular cavity. 
Doppler echocardiographic estimates of right ventricular systolic pressures 
can be obtained by measuring the velocity of the tricuspid regurgitant jet and 
by using the Bernoulli formula. 
Grading   Pulmonary hypertension 
< 31                                    Normal: 
31–35                                Borderline 
36–40                               Mild 
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 41–50                          Moderate 
>50        Severe.  
 
CD4 CELL COUNT    
 CD4 T-cell laboratory testing through flow cytometry is 
considered an essential part of HIV care, since this parameter is used to 
stage disease and guide clinical management. Certain CD4 T cell thresholds 
are used as reference  to either initiate prophylaxis against opportunistic 
infections (OIs) and/or to begin antiretroviral therapy. The CD4 cell count is 
also a relatively consistent indicator of treatment response. 
CD4 and CD8 T cells:15. 
 Human T lymphocytes can be functionally divided into cells that 
provide help for other immune cells and those that mediate cellular 
cytotoxicity. Helper T lymphocytes express CD4 ,whereas cytotoxic T cells 
express CD8. The CD4 and CD8 molecules are members of the 
immunoglobulin superfamily and mediate adhesion to major 
histocompatibility complex class II and class I molecules, respectively. 
 A CD4:CD8 ratio is calculated by dividing the number of CD4+ 
T cells by the number of CD8+ T cells; this ratio is usually greater than 1 in 
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immunocompetent individuals. However, in HIV infection, the CD4:CD8 
ratio is less than 1. This reflects increasing numbers of CD8+ T cells and 
depletion of CD4+ T cells in chronic infection. This ratio usually increases 
with the initiation of antiretroviral therapy. 
HIV and CD4 Cells: 
 CD4 cells are reduced precipitously in acute HIV infection, but 
usually rebound over several weeks as HIV-specific CD8 T cells help to 
lower plasma viremia. In the untreated patient, CD4 T cells subsequently 
decline over several years. 
 Subsequently, the CD4 cell count declines at an average yearly 
rate of approximately 50 cells/mm3. Significant depletion of CD4 T cells 
can lead to opportunistic infections and mortality in the untreated patient. 
 Treatment with ART leads to viral suppression and immunologic 
improvement; the extent of the immune recovery is dependent on the degree 
of immune compromise prior to treatment. Incomplete immunologic 
recovery among patients with advanced disease may be related to collagen 
formation in the gut and lymphoid tissues leading to disruption of normal 
architecture. 
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Normal CD4 cell count:  
 The normal adult CD4 count for most laboratories falls in a range 
of 800 to 1050 cells/mm3.When considering laboratory variations of two 
standard deviations, the normal CD4 cell count range falls within 500 to 
1400 cells/mm3. This broad range in normal values reflects the fact that the 
CD4 cell count is the product of three variables: the white blood cell count, 
the percentage of lymphocytes, and the percentage of lymphocytes that bears 
the CD4 receptor. 
Condition that affect CD4 count: 
 Infection  
 Medications  
 Alcohol abuse17. 
 Chronic conditions  
 Pregnancy. 
CD4 T CELL RESPONSE TO ANTIRETROVIRAL THERAPY:16. 
 With antiretroviral therapy and effective viral suppression, the 
expected CD4 cell response is an increase of 100 to 150 cells/mm3 at one 
year and an additional 20 to 50 cells/mm3 annually for the next three to five 
years. When ART is discontinued there is generally a rapid viral load 
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rebound and sharp decline in CD4 count  up to 100 to 150 cells/mL in three 
to four months. 
Factors that correlate with reduced CD4 recovery: 
 Older age, 
 Male sex, and  
 Type of ART used. 
ECHOCARDIOGRAPHIC FINDINGS IN PATIENTS WITH HIV       
INFECTION18. 
 In HIV-infected patients, concurrent pulmonary infections, 
pulmonary hypertension, anemia, portal hypertension, malnutrition, or 
malignancy can alter or confuse the characteristic signs that may be seen in 
heart failure in other populations. Thus, patients with left ventricular systolic 
dysfunction can present asymptomatic or can present with New York Heart 
Association Class III or IV heart failure. 
 Echocardiography is useful for assessing left ventricular systolic 
function in this population and, in addition to diagnosing left ventricular 
dysfunction, often reveals low to normal wall thickness or left ventricular 
hypertrophy and a dilated left ventricle. 
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 Echocardiography should be performed in any patient at elevated 
cardiovascular risk, with any clinical manifestations of cardiovascular 
disease, or with unexplained or persistent pulmonary symptoms or viral 
coinfections at baseline and every 1 to 2 years thereafter, or as clinically 
indicated. 
 Dilated cardiomyopathy was strongly associated with a CD4 
count lower than 100 cells/mL. 
 Clinical and echocardiographic findings suggest that diastolic 
dysfunction is relatively common in long-term survivors of HIV infection. 
 HIV-infected patients with pericardial effusions often have a 
lower CD4 count than those without effusions, indicating more advanced 
disease. Effusions are generally small and asymptomatic.Screening 
echocardiography is recommended for HIV-infected individuals, irrespective 
of the stage of Disease. 
 The CD4 count has been independently associated with survival 
in HIV PAH patients, and pulmonary hypertension was the direct cause of 
death in these patients. 
  
54 
 
MATERIAL AND METHODS 
SETTING: 
This study was conducted at the Institute of Internal Medicine, Rajiv 
Gandhi Government General Hospital,  ART Centre and Madras Medical 
College. 
ETHICAL COMMITTEE APPROVAL: 
Obtained. 
STUDY DURATION: 
This study was conducted over a period of six months. 
STUDY POPULATION: 
Patients admitted with HIV infection at medical wards, Institute of 
Internal medicine. 
SAMPLE SIZE: 
100 cases  
TYPE OF STUDY 
Cross sectional study.  
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INCLUSION CRITERION: 
 HIV infected adults with CD4 count < 500 
 
EXCLUSION CRITERIA: 
 Structural Heart Disease 
 Coronary Artery Disease 
 Systemic Hypertension 
 Diabetes mellitus 
 Thyroid disorders 
 Dyslipidemia 
DATA COLLECTION AND METHODS:Informed consent was 
obtained from each patient or the relative. 
Patients had their history taken according to a Questionnaire and were 
subjected to clinical examination. 
Patients are subjected to routine blood investigations like complete 
blood count, renal function tests, liver function tests; Fasting lipid profile, 
Thyroid function test,ECG, echocardiography and CD4 count will be done 
All the data were entered in the proforma (enclosed). 
Data were analyzed using SPSS package and ANOVA. 
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OBSERVATION AND RESULTS 
AGE DISTRIBUTION: 
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AGE AND CD4 COUNT: 
 
Age in 
years 
No. of patients with CD4 count (cells/mm3) 
 
 
 
 
 
 
p value 
 
0.098 
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21-30 
 
20 6 2  6 
31-40 21 4 9 4 
41-50 5 7 3 1 
≥50 3 0 1 2 
 
 
Age in years
> 5041-5031-4021-30< 20
Co
u
n
t
30
20
10
0
CD4 count
< 50
50-199
200-349
> 350
 SEX DISTRIBUTION:
 
 
 
 
SEX
MALE
FEMALE
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SEX AND CD4 COUNT: 
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 ART STATUS: 
 
 
 
 
 
ART STATUS
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NO 
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ART STATUS AND CD4 COUNT: 
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LVDD AMONG THE STUDY GROUP: 
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LVDD AND CD4 COUNT: 
 
LVDD 
(GRADE) No. of patients with CD4 count (cells/mm
3)  
 
 
 
 
 
 
p value 
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PEAND CD4 COUNT: 
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DCMAND CD4 COUNT: 
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EF AMONG THE STUDY GROUP: 
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EFAND CD4 COUNT: 
 
EF (%) No. of patients with CD4 count (cells/mm
3)  
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PAH AMONG THE STUDY GROUP: 
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PAHAND CD4 COUNT: 
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RESULTS 
Age distribution: 
 In this present study about 6% were in the age group <20years, 34% 
were in the age group of 21-30 years, 38% were in the age group of 31-40 
years and16% were in the group of 41-50 years and 6% were in the age 
group of >50 years. 
Age and CD4 count: 
In this present study, 66.7% of the patientsin the age group of 
<20years had a CD4 count of <50, 16.7% had a CD4 count between 50-
199,none had aCD4 countbetween 200-349 and 16.7% had a CD4 count 
of>350. 58.8% of the patients in the age group of 21-30 years had a CD4 
count of <50, 17.6% had a CD4 count between 50-199, 5.9% had aCD4 
count between 200-349 and 17.6% had a CD4 count of >350. 55.3% of the 
patients in the age group of 31-40years had a CD4 count of <50, 10.5% had 
a CD4 count between 50-199, 23.7% had aCD4 count between 200-349 and 
10.5% had a CD4 count of >350. 31.3% of the patients in the age group of 
41-50years had a CD4 count of <50, 43.8% had a CD4 count between 50-
199, 18.8% had aCD4 count between 200-349 and 6.3% had a CD4 count of 
>350. 50.0% of the patients in the age group of >50years had a CD4 count 
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of <50, none had a CD4 count between 50-199, 16.7% had aCD4 count 
between 200-349 and 33.3% had a CD4 count of >350.  Their comparison 
was not statistically significant (p value = 0.119).  
Sex distribution: 
 In our study about 66% were males and 34% were females.  
Sex and CD4 count: 
 In this present study, 56.1% of the males had a CD4 count of <50, 
19.7% had a CD4 count between 50-199, 12.1% had aCD4 count between 
200-349 and 12.1% had a CD4 count of >350. 47.1% of the females had a 
CD4 count of <50, 14.7% had a CD4 count between 50-199, 20.6% had 
aCD4 count between 200-349 and 17.6% had a CD4 count of >350.Their 
comparison was not statistically significant (p value = 0.529). 
ART status: 
 Among the 100 patients enrolled in this study, 86 were on ART and 
14 were ART naïve. 
ART status and CD4 count: 
 Among the 86 patients who were on ART, 61.6% had a CD4 count of 
<50, 20.9% had a CD4 count between 50-199, 17.4%  had a CD4 count 
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between 200-349 and none had a CD4 count of >350. All the 14 patients 
who were ART naïve had a CD4 count of >350. Their comparison was 
statistically significant (p value <0.001). 
LVDD: 
 Among the 100 patients, 15 had grade 0 LVDD; 13 had grade 1; 11, 
23 and 38 had grade 2, 3 and 4 LVDD respectively.   
LVDD and CD4 count: 
 Among the 15 patients with grade 0 LVDD, 20% had a CD4 count 
between 200-349 and 80% had a CD4 count of >350. Among the 13 patients 
with grade 1 LVDD, 15.4% had a CD4 count of <50, 7.7% had a CD4 count 
between 50-199, 69.2% % had a CD4 count between 200-349 and 7.7% had 
a CD4 count of >350. Among the 11 patients with grade 2 LVDD, 27.3% 
had a CD4 count of <50, 36.4% had a CD4 count between 50-199, 27.3% 
had a CD4 count between 200-349 and 9.1% had a CD4 count of >350. 
Among the 23 patients with grade 3 LVDD, 47.8% had a CD4 count of <50 
and 52.2% had a CD4 count between 50-199. Among the 38 patients with 
grade 4 LVDD, 97.4% had a CD4 count of <50 and 2.6% had a CD4 count 
between 50-199. Their comparison was statistically significant (p value < 
0.001). 
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PE: 
 Among the 100 patients, 14 had PE. 
PE and CD4 count: 
 Among the 14 patients, 78.6% had a CD4 count of <50 and 21.4% had 
a CD4 count between 50-199. Their comparison was statistically significant 
(p value = 0.014).   
DCM: 
 Among the 100 patients, 8 had DCM. 
DCM and CD4 count: 
 Among the 8 patients, 75% had a CD4 count of <50 and 25% had a 
CD4 count between 50-199. Their comparison was not statistically 
significant (p value = 0.086).  
EF: 
 Among the 100 patients, 43 had EF <30%; 26, 18 and 13 had EF of 
30-44%, 45-54% and ≥55% respectively. 
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EF and CD4 count: 
 Among the 43 patients with EF < 30%, 90.7% had a CD4 count of 
<50 and 9.3% had a CD4 count between 50-199. Among the 26 patients 
with EF 30-44%, 42.3% had a CD4 count of <50; 50% had a CD4 count 
between 50-199 and 7.7% had a CD4 count between 200-349. Among the 18 
patients with EF 45-54%, 16.7% had a CD4 count of <50; 5.6% had a CD4 
count between 50-199; 61.1% had a CD4 count between 200-349 and 16.7% 
had a CD4 count of >350. Among the 13 patients with EF ≥55%, 15.4% had 
a CD4 count between 200-349 and 84.6% had a CD4 count of >350. Their 
comparison was statistically significant (p value < 0.001). 
PAH: 
Among the 100 patients, 67 had RVSP <30mmHg; 14, 10, 6 and 3 had 
RVSP of 31-35mmHg, 36-40mmHg, 41-50mmHg and >50mmHg 
respectively. 
PAH and CD4 count: 
 Among the 67 patients who had a RVSP <30mmHg, 38.8% had a 
CD4 count of <50; 20.9% had a CD4 count between 50-199; 19.4% had 
aCD4 count between 200-349 and 20.9% had a CD4 count of >350. Among 
the 14 patients with RVSP 31-35mmHg, 78.6% had a CD4 count of <50; 
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14.3% had a CD4 count between 50-199 and 7.1% had a CD4 count between 
200-349. Among the 10 patients with RVSP 36-40mmHg, 80% had a CD4 
count of <50; 10% had a CD4 count between 50-199 and 10% had a CD4 
count between 200-349. Among the 6 patients with RVSP 41-50mmHg, 
83.3% had a CD4 count of <50 and 16.7% had a CD4 count between 50-
199. All  the 3 patients with RVSP >50mmHg had a CD4 count of <50. 
Their comparison was statistically significant (p value < 0.001). 
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DISCUSSION 
Number of patients taken up for study : 
Study groups Total number of cases 
Ayaskanta Singh et al12 70 
Mondy et al13 656 
Reinsh et al9 803 
Present study 100 
 
But no controls were used in this present study. 
AGE: 
Mean age of patients in various studies 
Ayaskanta Singhet al  Males   38.878.71 years 
Females     33.38±7.73 years  
Reinsh et al                                 Males   44.2± 10.3 years 
Females   40.3±9.2 years 
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Present study                        33±9.1 years 
The mean age of patients in this present study was lower than that of 
previous studies. 
GENDER: 
   Sex distribution of patients in various studies: 
Ayaskanta et alMales 45 (64.3%) 
Females 25 (35.7%) 
Mondy et al                               Males    501(76%) 
Females 155(24%) 
Present study                             Males 66(66%) 
                                                  Females   34(34%) 
       The male female ratio is comparable to other studies. 
CD4 COUNT: 
The Mean CD4 count was 
  Reinsh et al               509±301cells/mm3 
Present study             149.53±147.53cell/mm3 
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In this present study mean CD4 count is lower than the previous 
studies. 
Median CD4 count was  
Mondy et al             462 (326-661)cell/mm3 
Present study            48(24-491)cell/mm3 
     Our study has low median CD4 count. 
ART status: 
   Patients who were on ART 
Mondy et al                  478(73%) 
Present study                86(86%) 
EF: 
Mondy et al  found 533(82%) cases with EF >55% and 1(<1%) case with 
EF<35%.In our study we found 13(13%) cases with EF>55% and 43(43%) 
cases with EF<30%.In comparison our study had patients with  significant 
reduction in EF. 
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EF and CD4 count: 
Ayaskanta singh et al   studied patients with EF<50%  and foundCD4 
count <50 and CD4 count  50-199  were present in     9(56.2%) and 
6(37.5%) cases respectively.In our present study we studied patients with  
EF<30% and observed  CD4 count <50  and CD4 count 50-199  in 39( 
90.7%) and 4( 9.3%) cases respectively.In the  former study EF was not 
stratified below <50%. 
LVDD: 
Mondy et al   found 477(74%) cases with GR 0 and 61(9%) cases with 
GR 3 LVDD.In our study we found 15(15%) cases with GR 0 and 38(38%) 
cases with GR 4 LVDD .In comparison our study had patients with  
significant LVDD. 
LVDD and CD4Count: 
Ayaskanta singh et al   studied patients with   LVDD and found  CD4 
count <50 and CD4 count  50-199  were  present in    3 (50%) and 2 (33.3%) 
cases respectively.In our present study we studied patients with   LVDD GR 
4 and observed  CD4 count <50  and CD4 count 50-199  in 37(97.4 %) and 
1( 2.6%) cases respectively. In the former study LVDD was not stratified 
with grading. 
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PAH: 
Mondy et al   found 139(43%) cases with RVSP <31mmHg and 
5(2%) cases with RVSP≥50.In our study we found 67(67%) cases with 
RVSP <31 and 3(3%) cases with RVSP ≥50.In comparison our study had 
patients with  significant PAH. 
PAH and CD4: 
Ayaskanta singh et al   studied patients with   PAH  and observed  
CD4 count <50 and CD4 count  50-199  in     3(37.5%) and 4(50%) cases 
respectively. In our present study we found RVSP ≥50  and CD4 count <50   
in 3(100%)  cases.In the former study PAH was not graded according to 
RVSP mm Hg. 
DCM and CD4 count: 
Ayaskanta singh et al   studied patients with   DCMand found CD4 
count <50 and CD4 count  50-199  were  present in     5(83.3%) and 
1(16.7%) cases respectively. In our present study we had patients with  
DCM and observed  CD4 count <50  and CD4 count 50-199  in 6(75%) and 
2( 25%) cases respectively. Our study results were comparable to the 
former study.  
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PE and CD4: 
Ayaskanta singh et al   studied patients with   PE and found CD4 
count <50 and CD4 count  50-199  in    8 (66.7%) and 2 (16.7%) cases 
respectively. In our present study we had patients with  DCM and CD4 
count <50  and CD4 count 50-199  in 11(78.6 %) and 3(21.4 %) cases 
respectively. 
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LIMITATIONS OF STUDY 
 One limitation of this study was less number of patients. 
 As this study was a cross-sectional study follow up of patients could 
not be done to assess the clinical improvement resulting from 
HAART. 
 This study did not include a suitable HIV-seronegative control group. 
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                                          CONCLUSION 
 
 Cardiovascular manifestations are common in HIV infected patients  
and often subclinical. 
 Echocardiography is a useful technique for the early recognition and 
treatment of cardiac abnormalities. 
 CD4 count correlates well with Echocardiographic findings. 
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PROFORMA 
A STUDY ON ECHOCARDIOGRAPHIC FINDINGS IN HIV-
INFECTED PATIENTS AND THEIR CORRELATION WITH 
CD4COUNT 
 
Name : Patient ID No: 
Age/Sex : 
IP No : 
 
Presenting complaints 
  Dyspnea   Oliguria 
  Orthopnea   Abdominal distension 
  PND   Swelling of legs 
  Chest pain   Others  
 
Past history 
 Diabetes mellitus  Coronary artery disease 
 Hypertension   Other comorbid illnesses 
 
Personal history 
 Smoking   Alcoholism  
 
ART status 
 Yes – duration:  No  
 
CLINICAL PARAMETERS 
Pulse  Blood Pressure  
 General examination 
 
Systemic examination 
CVS: RS: 
P/A: CNS: 
 
 
Investigations 
RFT LFT 
Glucose 
(F)                                                                                         
(PP) 
 
 
mg/dl
Total bilirubin 
 
mg/dl 
 
mg/dl 
Urea 
 
mg/dl Direct bilirubin 
 
mg/dl 
Creatinine 
 
mg/dl SGOT 
 
U/l 
Na+ 
 
mEq/l SGPT 
 
U/l 
K+ 
 
mEq/l ALP 
 
U/l 
 
Total protein 
 
g/dl 
Albumin 
 
g/dl 
Hemogram Lipid profile 
TC 
 
cells/mm3 Total 
cholesterol  mg/dl 
DC 
 LDL  mg/dl 
ESR 
 mm/hr HDL  mg/dl 
Hb 
 g/dl Triglycerides  mg/dl 
PCV 
 %               Thyroid function test 
Platelets 
 lakhs/mm3 T3  ng/dL 
RBCs 
 million/mm3 T4  µg/dL 
TSH 
 µIU/mL 
CD4 count  
 
Chest X-ray: 
 
ECG: 
 
Echocardiography: 
 
 
 
 
 
 
 
 
 
 
PATIENT CONSENT FORM 
Study Detail : “A STUDY ON ECHOCARDIOGRAPHIC FINDINGS 
IN HIV-INFECTED PATIENTS AND THEIR 
CORRELATION WITH CD4 COUNT” 
 
Study Centre : Rajiv Gandhi Government General Hospital, 
Chennai. 
Patient’s Name :  
Patient’s Age :  
Identification 
Number 
:  
Patient may check (☑) these boxes 
I confirm that I have understood the purpose of procedure for the above 
study. I have the opportunity to ask question and all my questions and 
doubts have been answered to my complete satisfaction. ❏ 
I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time without giving reason, without my legal 
rights being affected. ❏ 
I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities 
will not need my permission to look at my health records, both in 
respect of current study and any further research that may be conducted ❏ 
in relation to it, even if I withdraw from the study I agree to this access. 
However, I understand that my identity will not be revealed in any 
information released to third parties or published, unless as required 
under the law. I agree not to restrict the use of any data or results that 
arise from this study. 
I agree to take part in the above study and to comply with the 
instructions given during the study and faithfully cooperate with the 
study team and to immediately inform the study staff if I suffer from 
any deterioration in my health or wellbeing or any unexpected or 
unusual symptoms. ❏ 
I hereby consent to participate in this study. ❏ 
I hereby give permission to undergo complete clinical examination and 
diagnostic tests including haematological, biochemical, radiological 
tests. ❏ 
 
Signature/thumb impression          Signature of Investigator 
 
Patient’s Name and Address:       Study Investigator’s Name: 
 
 
DR. PAKKEER KANNU SYED FAHRUDEEN MUNNAVER 
 
S. NO AGE SEX ART 
status 
CD4 
count 
EF LVDD 
(GRADE) 
PAH PE DCM 
1 21 F Y 88 29 4 48 Y N 
2 31 M Y 262 38 2 26 N N 
3 22 F N 422 58 0 24 N N 
4 30 M Y 132 38 3 28 N N 
5 31 F Y 41 42 3 30 N N 
6 21 M Y 33 29 4 46 N N 
7 41 F Y 124 38 3 30 N N 
8 41 M Y 340 58 1 24 N N 
9 32 F N 486 60 0 26 N N 
10 42 M Y 311 48 2 26 N N 
11 32 M Y 28 27 4 61 Y N 
12 19 F Y 24 28 4 55 Y N 
13 22 M Y 31 25 4 44 N N 
14 51 M Y 44 40 3 28 N Y 
15 33 F Y 322 50 1 26 N N 
16 23 F N 472 62 0 25 N N 
17 19 M Y 152 37 3 26 N N 
18 23 M Y 46 52 1 30 N N 
19 33 M Y 44 39 2 28 N N 
20 24 M Y 37 28 4 38 N N 
21 34 F Y 40 43 3 30 N N 
22 52 M Y 48 51 2 28 N N 
23 29 M Y 167 40 2 28 N N 
24 34 M Y 288 49 1 26 N N 
25 53 M N 388 60 0 26 N N 
26 35 M Y 47 38 3 30 N N 
27 54 M Y 28 25 4 62 Y N 
28 24 F Y 35 27 4 48 N N 
29 36 M Y 37 28 4 46 N N 
30 25 M Y 99 38 3 34 N N 
31 28 M Y 264 47 1 38 N N 
32 35 F N 416 56 0 25 N N 
33 43 M Y 149 36 3 28 N N 
34 37 M Y 39 29 4 37 N N 
35 42 F Y 40 29 4 39 N Y 
36 25 F Y 45 39 3 28 N N 
37 48 M Y 117 37 3 30 Y N 
38 38 M Y 238 47 1 34 N N 
39 51 F N 449 61 0 26 N N 
40 26 M Y 138 38 3 26 N N 
41 36 F Y 49 43 3 30 Y N 
42 20 M Y 40 28 3 36 N N 
43 44 M Y 175 43 3 30 N N 
44 39 M Y 337 60 0 28 N N 
45 27 M N 377 53 1 24 N N 
46 40 M Y 71 28 3 38 N Y 
47 37 F Y 41 28 3 30 Y N 
48 27 M Y 39 27 4 38 N N 
49 26 F Y 35 26 4 39 N N 
50 31 M Y 43 41 2 28 N N 
51 49 M Y 37 28 4 30 N Y 
52 32 M Y 39 26 4 28 N N 
53 27 F Y 47 41 3 30 N N 
54 28 M Y 43 29 4 28 N N 
55 50 M Y 188 52 2 28 Y N 
56 38 F Y 289 49 1 26 N N 
57 33 M N 408 51 2 25 N N 
58 21 M Y 42 26 4 34 N N 
59 31 M Y 40 28 4 30 N N 
60 45 M Y 37 25 4 38 N N 
61 34 M Y 33 24 4 48 N N 
62 39 F Y 331 52 1 26 N N 
63 19 M N 434 58 0 26 N N 
64 43 F Y 151 29 3 26 N N 
65 28 F Y 31 24 4 32 N N 
66 29 M Y 38 29 4 33 N N 
67 35 M Y 48 29 4 32 N N 
68 26 M Y 45 29 4 34 N N 
69 41 M Y 41 28 4 33 Y Y 
70 40 F Y 40 28 4 35 N N 
71 36 M Y 35 25 4 38 Y N 
72 31 F Y 172 42 3 26 N N 
73 29 F N 461 60 0 25 N N 
74 37 M Y 74 28 3 33 N Y 
75 25 M Y 48 29 4 30 N N 
76 32 F Y 38 28 4 30 N N 
77 38 M Y 33 27 4 28 Y Y 
78 30 F Y 325 51 1 26 N N 
79 46 M Y 29 24 4 30 Y N 
80 30 M Y 41 29 4 28 N N 
81 33 F Y 223 50 1 28 N N 
82 42 M N 491 60 0 25 N N 
83 39 M Y 171 41 2 26 N N 
84 24 M Y 38 28 4 30 N N 
85 20 M Y 47 50 1 28 N N 
86 34 F Y 48 41 3 35 N N 
87 40 M Y 34 28 4 34 Y N 
88 52 F Y 316 51 0 26 N N 
89 22 M N 372 52 0 25 N N 
90 44 F Y 113 40 2 28 N N 
91 23 M Y 33 25 4 33 N N 
92 30 F Y 49 43 3 30 N N 
93 35 F Y 262 49 0 26 N N 
94 32 M N 456 63 0 24 N N 
95 22 M Y 129 38 1 28 N N 
96 20 M Y 44 29 4 32 N N 
97 23 M Y 47 29 4 28 N N 
98 36 F Y 40 28 4 30 Y Y 
99 47 M Y 241 39 2 28 N N 
100 21 M N 463 61 0 24 N N 
 
  
 
 
 
 
 
 
 
 
 
